Reata Pharmaceuticals, Inc. (RETA) Can’t Burn Your Long Portfolio. Has Another Strong Session

March 14, 2018 - By Migdalia James

The stock of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) is a huge mover today! The stock increased 4.55% or $1.07 during the last trading session, reaching $24.57. About 220,043 shares traded or 5.38% up from the average. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 8 months positive chart setup for the $642.63 million company. It was reported on Mar, 14 by We have $26.54 PT which if reached, will make NASDAQ:RETA worth $51.41 million more.

Analysts await Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report earnings on May, 10. They expect $-0.66 earnings per share, down 106.25 % or $0.34 from last year’s $-0.32 per share. After $-0.64 actual earnings per share reported by Reata Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.13 % negative EPS growth.

More important recent Reata Pharmaceuticals, Inc. (NASDAQ:RETA) news were published by: which released: “Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2017 …” on March 02, 2018, also published article titled: “Reata Pharmaceuticals A Buy On Bardoxolene Data”, published: “Novo A Buys OrthoPediatrics Corp, Glaukos Corp, Sells AnaptysBio Inc, Flexion …” on March 13, 2018. More interesting news about Reata Pharmaceuticals, Inc. (NASDAQ:RETA) was released by: and their article: “Reata Pharma (RETA) Reports Top-Line Data from Dose-Escalation Cohorts of …” with publication date: March 01, 2018.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $642.63 million. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreich's ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.